# Alkermes plc (ALKS) Stock Analysis: A Promising 38% Upside in the Healthcare Sector

- Link: https://www.directorstalkinterviews.com/alkermes-plc-alks-stock-analysis-a-promising-38-upside-in-the-healthcare-sector/4121221849
- Published: 2025-10-20T10:46:36+01:00
- Author: Madison Wilson

Alkermes plc (NASDAQ: ALKS), a leading biopharmaceutical company headquartered in
Dublin, Ireland, is capturing investor interest with a potential 38.02% upside, 
as suggested by current analyst ratings. Specializing in the development of treatments
for neurological disorders and dependency issues, Alkermes is a prominent player
in the healthcare sector, specifically within the drug manufacturers – specialty
and generic industry.

The company boasts a robust market capitalization of $5 billion, reflecting its 
significant presence in the global pharmaceutical landscape. Currently trading at
$30.26, Alkermes’ stock is near the midpoint of its 52-week range of $25.70 to $
36.00. Despite a slight dip of 0.54% in its recent price change, the stock is poised
for potential growth, as evidenced by the average target price of $41.76 set by 
analysts.

Alkermes has made significant strides with key products like ARISTADA for schizophrenia
and VIVITROL for alcohol and opioid dependence. These offerings are crucial for 
addressing unmet medical needs in both the US and international markets. Additionally,
the company’s collaboration agreements with pharmaceutical giants like Janssen Pharmaceutica
enhance its research and development capabilities, potentially leading to innovative
solutions in the biopharmaceutical space.

From a valuation perspective, Alkermes presents a forward P/E ratio of 20.32, indicating
reasonable expectations of earnings growth. While traditional metrics such as trailing
P/E and PEG ratios are unavailable, the company’s strong return on equity of 23.94%
signals effective management and operational efficiency. Furthermore, Alkermes’ 
free cash flow of approximately $345.7 million underscores its financial stability
and capacity to reinvest in growth initiatives.

Despite a slight decline in revenue growth at -2.10%, Alkermes’ earnings per share(
EPS) stands at an impressive 2.07, reflecting its ability to generate profits in
a challenging market environment. The lack of a dividend yield and a payout ratio
of 0.00% suggest that the company is focused on reinvesting earnings to fuel future
growth rather than distributing profits to shareholders.

Alkermes has garnered favorable attention from analysts, with 14 buy ratings and
only four holds, and no sell ratings. This bullish sentiment is further supported
by the technical indicators, where the stock’s 50-day moving average of 29.09 and
200-day moving average of 30.21 suggest a stable upward trend. The Relative Strength
Index (RSI) of 57.48 and a slightly positive MACD of 0.78 indicate modest bullish
momentum, reinforcing the stock’s potential for appreciation.

As Alkermes continues to innovate in the biopharmaceutical domain, its strategic
focus on addressing critical therapeutic areas presents a compelling case for investors
seeking exposure to the healthcare sector. With a promising pipeline and strong 
market positioning, Alkermes plc is a stock to watch for those interested in capitalizing
on its growth trajectory and the substantial upside it presents.

Share on:
